Expanded Approval Isn't a Sure Thing

Amarin (NASDAQ: AMRN  ) has moved one step closer to substantially expanding the potential market for its fish oil Vascepa. On Tuesday, the biotech said it submitted its application to the Food and Drug Administration to market Vascepa in patients with high triglycerides levels, between 200 mg/dL and 500 mg/dL.

Vascepa is already approved to treat patients with extremely high triglyceride levels above 500 mg/dL. The data for patients with triglyceride levels from 200 mg/dL to 500 mg/dL has been out for nearly two years. Vascepa reduced triglycerides by a placebo-adjusted 21.5% at the higher dose. The drug also lowered bad cholesterol levels when used in combination with a statin such as Pfizer's (NYSE: PFE  ) Lipitor, AstraZeneca's (NYSE: AZN  ) Crestor, or Merck's (NYSE: MRK  ) Zocor. That's pretty impressive since statins do a pretty good job of lowering cholesterol on their own.

What took Amarin so long to file for approval? Blame it on the FDA.

The agency compromised with Amarin, agreeing to accept laboratory tests as surrogate endpoints as long as the company had substantially enrolled a clinical trial called Reduce-It that tests Vascepa's ability to lower heart problems -- strokes, heart attacks, and the like.

Clinical outcomes data will be nice to have when we get it, but just the ability to market Vascepa to patients with triglyceride levels as low as 200 mg/dL is a huge win for Amarin even if it can only claim changes in triglyceride and cholesterol levels. The number of patients with triglyceride levels between 200 mg/dL and 500 mg/dL is nearly ten times higher than the number of patients Vascepa is currently approved to treat.

The clinical laboratory data are solid, but investors should keep in mind there's a possibility, however slight, that the FDA reverses course, demanding outcomes data before making the expanded approval.

That would be a travesty; what's the point of coming to an agreement if the FDA is just going to change its mind? But the FDA always reserves the right to change its mind if new data become available, and there have been a couple of recent high-profile cardiovascular studies where drugs have shown to improve laboratory tests but not clinical outcomes, most recently with Merck's Cordaptive. Those studies will be in the back of the FDA's mind as it reviews the expanded approval.

Can Amarin beat the odds?
Small biotech companies usually crash and burn when it comes to launching drugs -- but can Amarin prove the doubters wrong with its new lipid-lowering drug? In our new premium research report, The Motley Fool's top biotech analyst offers an in-depth look at this drugmaker's upcoming opportunities, along with reasons to buy and sell this stock today. To find out more -- and receive a full year of free bonus updates as news develops -- simply click here now to claim your copy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2452438, ~/Articles/ArticleHandler.aspx, 12/21/2014 12:34:53 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 17,804.80 26.65 0.15%
S&P 500 2,070.65 9.42 0.46%
NASD 4,765.38 16.98 0.36%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/19/2014 4:00 PM
AMRN $1.13 Up +0.08 +7.62%
Amarin Corp plc (A… CAPS Rating: ****
AZN $71.69 Down -0.42 -0.58%
AstraZeneca plc (A… CAPS Rating: ****
MRK $59.58 Up +0.60 +1.02%
Merck & Co., Inc. CAPS Rating: ****
PFE $31.94 Down -0.03 -0.09%
Pfizer CAPS Rating: ****

Advertisement